Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal

1861 - Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology


08 Oct 2016


Gastrointestinal tumours, non-colorectal


Takuji Okusaka


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


T. Okusaka1, J. Blanc2, I. Chau3, L. Yang4, P. Abada5, A.X. Zhu6

Author affiliations

  • 1 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Hepato-gastroenterology And Digestive Oncology, Hôpital Saint-André, Bordeaux/FR
  • 3 Department Of Medicine, Royal Marsden NHS Foundation Trust, London and Surrey/GB
  • 4 Biostatistics, Eli Lilly and Company, Bridgewater/US
  • 5 Oncology, Eli Lilly and Company, Indianapolis/US
  • 6 Department Of Medicine, Massachusetts General Hospital Cancer Center, Boston/US


Abstract 1861


REACH was a global, randomized, phase 3 study evaluating the efficacy and safety of single-agent RAM in pts with advanced HCC after prior sorafenib. While a significant median overall survival (OS) benefit was not observed in the ITT population (N = 565), a survival benefit was observed in pts with a baseline alpha-fetoprotein (AFP) ≥400 ng/mL (n = 250), OS 7.8 mo RAM vs 4.2 mo placebo [PBO], HR 0.67; P= .006). Ad hoc retrospective analyses on the survival and safety of pts by liver disease etiology were performed.


In each disease etiology subgroup (Hepatitis B [HepB], HepC, or Other) per case report form, OS was estimated using Kaplan-Meier analysis and compared by log-rank test and Cox proportional hazards model. The objective response rate (ORR) was defined as the proportion of pts with best overall response of CR or PR.


Baseline pt characteristics were generally balanced between treatment arms in each subgroup. 37% were reported as HepB (n = 209), 27% HepC (n = 154), and 36% Other (n = 202). HepB pts were more likely to be Asian, ECOG PS 1, have extra-hepatic spread, and AFP ≥400ng/mL. The OS for RAM compared to PBO was 8.2 vs 5.4 mo in HepB (HR 0.79; P= .11); 9.2 vs 8.8 mo in HepC (HR 0.95; P = .79); and 11.1 vs 8.5 mo in Other pts (HR 0.85; P= .33). ORR was 2.8% RAM vs 0% PBO in HepB pts, 10.3% vs 2.6% in HepC pts, and 9.1% vs 0% in Other pts. In pts with baseline AFP ≥400 ng/mL, the OS for RAM compared to PBO was 6.6 vs 4.0 mo in HepB (HR 0.67; P= .04); 8.2 vs 4.8 mo in HepC (HR 0.89; P= .68); and 8.5 vs 4.3 mo in Other pts (HR 0.45; P= .003). In all subgroups with baseline AFP


HepB pts had shorter survival compared to pts with HepC or Other. In all etiology subgroups with a baseline AFP ≥400 ng/mL, a potential improvement in survival with RAM was observed. RAM was well tolerated with a similar safety profile in all etiology subgroups.

Clinical trial identification


Legal entity responsible for the study

Eli Lilly and Company


Eli Lilly and Company


T. Okusaka: Honoraria, Consulting/Advisory roles: Eli Lilly, BMS, Merck, Blueprint, Eisai, Biocompatibles, Guerbert, Roche, Bayer, Genentech, Boehringer-Ingelheim, GSK, Celsion, Novartis. Research funding: Eli Lilly, Bayer, Novartis, Boehringer-Ingelheim. J.-F. Blanc: Advisory Board: Lilly Oncology, Bayer SP.

I. Chau: Honoraria: Taiho, Pfizer, Amgen, Eli-Lilly, Bayer. Advisory role: Sanofi Oncology, Eli-Lilly, Bristol Meyers Squibb, Merck Serono, MSD, Gilead Science. Research funding: Janssen-Cilag, Sanofi Oncology, Roche, Merck-Serono. L. Yang, P. Abada: Employee and stock owner of Eli Lilly and Company. A.X. Zhu: Funding: Eli Lilly and Company.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings